NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Individuals Who Provided Content Development and/or Authorship Assistance

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

John L. Gore, MD, MS, Panel Member
Ryan Schonfeld, BA, Guidelines Coordinator, NCCN
MaryElizabeth Stein, PhD, Associate Scientist/Medical Writer, NCCN
Lisa A. Gurski, PhD, Manager, Licensed Clinical Content, NCCN

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Robert J. Motzer, MD, Panel Chair, has disclosed receiving grant/research support from AVEO Pharmaceuticals, Inc., Bristol Myers Squibb, Eisai Inc., Exelixis Inc., Merck & Co., Inc., and Pfizer Inc.; and serving as a consultant for Merck & Co., Inc., and Takeda Pharmaceuticals North America, Inc.
Eric Jonasch, MD, Panel Vice Chair, has disclosed serving as a consultant for AVEO Pharmaceuticals, Inc., Eisai Inc., Exelixis, Inc., Ipsen, Merck & Co., Inc., NiKang Therapeutics, Inc., and Novartis Pharmaceuticals Corporation; and receiving grant/research support from Arrowhead Pharmaceuticals, AVEO Pharmaceuticals, Inc., Corvus Pharma, Merck & Co., Inc., NiKang Therapeutics, Inc., and ProfoundBio.
Naomi Haas, MD, Panel Member, has disclosed serving as a paid consultant for Bristol Myers Squibb, and Eisai Inc.; and serving as a nonpaid consultant for Pfizer Inc.
Payal Kapur, MD, Panel Member, has disclosed serving as a consultant for ClearNano Inc.
M. Dror Michaelson, MD, PhD, Panel Member, has disclosed serving as a scientific advisor for Eisai Inc., Janssen Pharmaceutica Products, LP, and Merck & Co., Inc.
Amir Mortazavi, MD, Panel Member, has disclosed receiving grant/research support from Astellas Pharma US, Inc., Bristol Myers Squibb, Genentech, Inc., GSK, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, and Seagen.
Brian Shuch, MD, Panel Member, has disclosed serving as a consultant for Genentech, Inc., Johnson & Johnson,Merck & Co., Inc., Telix Pharmaceuticals and Veracyte.
Jeffrey Sosman, MD, Panel Member, has disclosed serving as a consultant for Jazz Pharmaceuticals, Inc., and Pfizer Inc.; and serving as a scientific advisor for Pfizer Inc.

View all of the conflicts of interest for the NCCN Guidelines panel

NCCN Staff Disclosures

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.